These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31030419)

  • 1. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F; Smith P; Gebrye T; Yeowell G
    BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O; Kindundu CM; Barbeau M; LeLorier J
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates.
    Ojeda-Bruno S; Naranjo A; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Quevedo JC; Rodríguez-Lozano C
    Osteoporos Int; 2011 Jun; 22(6):1821-8. PubMed ID: 20924747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Innovation of bisphosphonates for improvement of adherence.].
    Takeuchi Y
    Clin Calcium; 2017; 27(2):197-202. PubMed ID: 28123121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
    Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
    BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
    Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
    Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.